Home > Boards > US Listed > Biotechs > Agios Pharmaceuticals, Inc. (AGIO)

AGIO $47.39

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ClearlyStocks Member Profile
 
Followed By 554
Posts 40,762
Boards Moderated 2
Alias Born 06/08/06
160x600 placeholder
Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones GlobeNewswire Inc. - 1/12/2020 4:00:10 PM
Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 GlobeNewswire Inc. - 12/23/2019 7:00:10 AM
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relap... GlobeNewswire Inc. - 12/16/2019 4:00:10 PM
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficie... GlobeNewswire Inc. - 12/9/2019 10:00:10 AM
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute M... GlobeNewswire Inc. - 12/9/2019 8:00:10 AM
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Result... GlobeNewswire Inc. - 12/8/2019 9:00:10 AM
Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer GlobeNewswire Inc. - 12/2/2019 7:00:10 AM
Agios Appoints Jonathan Biller as Chief Legal Officer GlobeNewswire Inc. - 11/25/2019 7:00:10 AM
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire Inc. - 11/13/2019 10:21:25 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/8/2019 5:04:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/8/2019 4:57:57 PM
Agios Announces Pricing of $256 Million Public Offering of Common Stock GlobeNewswire Inc. - 11/7/2019 9:17:50 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/6/2019 4:09:20 PM
Agios Announces Proposed Offering of Common Stock GlobeNewswire Inc. - 11/6/2019 4:01:00 PM
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH ... GlobeNewswire Inc. - 11/6/2019 9:28:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 5:10:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/31/2019 9:16:06 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/31/2019 7:39:46 AM
Agios Reports Business Highlights and Third Quarter 2019 Financial Results GlobeNewswire Inc. - 10/31/2019 7:00:05 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2019 7:20:50 AM
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTA... GlobeNewswire Inc. - 10/27/2019 11:50:05 AM
Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019 GlobeNewswire Inc. - 10/17/2019 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/9/2019 4:20:59 PM
Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Or... GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/30/2019 11:14:11 AM
ClearlyStocks   Wednesday, 09/07/16 11:11:13 AM
Re: None
Post # of 49 
AGIO $47.39

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist